<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(3)</volume><submitter>Yin N</submitter><pubmed_abstract>&lt;b>Background:&lt;/b> Glutathione (GSH) is an essential antioxidant that protects against oxidative stress, but its oral bioavailability is below 1% due to enzymatic degradation and poor gastrointestinal absorption. Improving the oral bioavailability of GSH could significantly enhance its therapeutic efficacy. &lt;b>Methods:&lt;/b> This study synthesised GSH analogues with chemical modifications to improve bioavailability. Seven GSH derivatives were designed: three analogues with altered stereochemistry (&lt;b>1.62&lt;/b>, &lt;b>1.63&lt;/b>, and &lt;b>1.64&lt;/b>) and three &lt;i>N&lt;/i>-methylated derivatives (&lt;b>1.65&lt;/b>, &lt;b>1.70&lt;/b>, and &lt;b>1.71&lt;/b>), alongside a native GSH (&lt;b>1.61&lt;/b>). The analogues were synthesised via Fmoc-solid-phase peptide synthesis, and they were characterised using reverse-phase high-perform</pubmed_abstract><journal>Pharmaceutics</journal><pagination>385</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11945201</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Enhancing the Oral Bioavailability of Glutathione Using Innovative Analogue Approaches.</pubmed_title><pmcid>PMC11945201</pmcid><pubmed_authors>Wen J</pubmed_authors><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>Chen G</pubmed_authors><pubmed_authors>Yin N</pubmed_authors><pubmed_authors>Brimble MA</pubmed_authors><pubmed_authors>Harris PWR</pubmed_authors><pubmed_authors>Sun J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Enhancing the Oral Bioavailability of Glutathione Using Innovative Analogue Approaches.</name><description>&lt;b>Background:&lt;/b> Glutathione (GSH) is an essential antioxidant that protects against oxidative stress, but its oral bioavailability is below 1% due to enzymatic degradation and poor gastrointestinal absorption. Improving the oral bioavailability of GSH could significantly enhance its therapeutic efficacy. &lt;b>Methods:&lt;/b> This study synthesised GSH analogues with chemical modifications to improve bioavailability. Seven GSH derivatives were designed: three analogues with altered stereochemistry (&lt;b>1.62&lt;/b>, &lt;b>1.63&lt;/b>, and &lt;b>1.64&lt;/b>) and three &lt;i>N&lt;/i>-methylated derivatives (&lt;b>1.65&lt;/b>, &lt;b>1.70&lt;/b>, and &lt;b>1.71&lt;/b>), alongside a native GSH (&lt;b>1.61&lt;/b>). The analogues were synthesised via Fmoc-solid-phase peptide synthesis, and they were characterised using reverse-phase high-perform</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-07-04T03:06:04.246Z</modification><creation>2025-07-04T03:06:04.246Z</creation></dates><accession>S-EPMC11945201</accession><cross_references><pubmed>40143049</pubmed><doi>10.3390/pharmaceutics17030385</doi></cross_references></HashMap>